Abstract
The continuous growth of tumors depends on the altered regulation of the cell cycle, which is in turn modulated by signals from growth factors and their receptors. Blockade of insulin-like growth factor (IGF)-I and IGF-IR by antisense or dominant negative plasmid transfection can suppress tumorigenicity and induce regression of established tumors. We have constructed two recombinant adenoviruses: an adenovirus expressing truncated IGF-IR (ad-IGF-IR/950) with an engineered stop codon at amino acid residue 950, and an adenovirus expressing the soluble extracellular domain of IGF-IR (ad-IGF-IR/482) with an engineered stop codon at amino acid residue 482. Ad-IGF-IR/950 produces a defective receptor with an intact α subunit and a defective β subunit lacking the tyrosine kinase domain. Dominant negative inhibition results from competition of the defective receptor with normal IGF-IR subunits, or the competition with normal IGF-IR for ligand by the soluble receptor. We were able to show here that ad-IGF-IR/950 induced the increased expression of IGF-IR on the cell surface and ad-IGF-IR/482 induced the secretion of the soluble fragment of IGF-IR. The transduction of both ad-IGF-IR/950 and ad-IGF-IR/482 could blunt the growth-stimulatory effect of IGF-I on human lung cancer cell lines. Both ad-IGF-IR/950 and ad-IGF-IR/482 effectively blocked IGF-I–induced Akt kinase activation. Intratumoral injection of ad-IGF-IR/482 virus showed significant growth suppression in established lung cancer xenografts. These findings suggest that these ad-IGF-IR/dn (950, 482) have the potential to be effective and practical cancer gene therapy strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baserga R . Oncogenes and the strategy of growth factor. Cell. 1994; 79: 927–930.
Ullrich A, Gray A & Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5: 2503–2512.
Baserga R . The IGF-I receptor in cancer research. Exp Cell Res. 1999; 253: 1–6.
Baserga R . The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997; 1332: F105–F126.
Resnikoff M, Sell C & Rubini M, et al. Rat glioblastoma cells expressing an antisense RNA to insulin-like growth factor I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 1994; 54: 2218–2222.
Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S & Baserga R . Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 1994; 54: 4848–4850.
Prager D, Li HL, Asa S & Melmed S . Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA. 1994; 91: 2181–2185.
Miura M, Li S & Baserga R . Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. Cancer Res. 1995; 55: 663–667.
Burgaud JL, Resnikoff M & Baserga R . Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem Biophys Res Commun. 1995; 214: 475–481.
Reiss K, D'Ambrosio C, Tu X, Tu C & Baserga R . Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res. 1998; 4: 2647–2655.
Dunn SE, Ehrlich M & Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998; 58: 3353–3361.
Rininsland F, Johnson TR & Chernicky CL, et al. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA. 1997; 94: 5854–5859.
Graham FL & Prevec L . Manipulation of adenovirus vectors. In: Murray E, edGene Transfer and Expression Protocols, Clifton, NJ: Humana Press; 1991; 109–128.
Tang DC, Johnston SA & Carbone DP . Tumor-restricted gene expression by adenovirus-mediated gene transfer. Cancer Gene Ther. 1994; 1: 15–20.
Lee C-T, Wu S & Gabrilovich D, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 1996; 56: 3038–3041.
Becker TC, Noel RJ & Coats WS, et al. Use of recombination of adenovirus for metabolic engineering of mammalian cells. In: Roth MG, edProtein Expression in Animal Cells, New York: Academic Press; 1994; 161–188.
Kim SO, Park JG & Lee YI . Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene products. Cancer Res. 1996; 56: 3831–3836.
Kulik G, Klippel A & Weber MJ . Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1998; 18: 1595–1606.
Kulik G & Weber MJ . Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor-I. Mol Cell Biol. 1998; 18: 6711–6718.
Grimberg A & Cohen P . Growth hormone and prostate cancer: guilty by association?. J Endocrinol Invest. 1999; 22: 64–73.
Ma J, Pollack MN & Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999; 91: 620–625.
Yu H, Spitz MR, Mistry J, Gu J, Hong WK & Wu X . Plasma levels of insulin-like growth factor-I and lung cancer risk: a case control analysis. J Natl Cancer Inst. 1999; 91: 151–156.
Scotland K, Benini S & Nani P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic nude mice. Cancer Res. 1999; 58: 4127–4131.
Trojan J, Blossey BK & Johnson TR, et al. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA. 1992; 89: 4874–4878.
Hongo A, Yumet G, Resnicoff M, Romano G, O'Connor R & Baserga R . Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristoylated COOH terminus of insulin-like growth factor I receptor. Cancer Res. 1998; 58: 2477–2484.
Datta SR, Dudek H & Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91: 231–241.
del Peso L, Gonzalez-Garcia M, Page C, Herrera R & Nunez G . Interleukin-3–induced phosphorylation of BAD through the protein kinase Akt. Science. 1997; 278: 687–689.
Parrizas M, Saltiel AR & LeRoith D . Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997; 272: 154–161.
Peruzzi F, Prisco M & Dews M, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999; 19: 7203–7215.
D'Ambrosio C, Ferber A, Resnicoff M & Baserga R . A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 1996; 56: 4013–4020.
Jiang Y, Rom WN, Yie T-A, Chi CX & Tchou-Wong K-M . Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene. 1999; 18: 6071–6077.
Acknowledgements
This work is supported by Grants from the Medical Research Center from Seoul National University (2000) to C-T Lee and DP Carbone (NCI 5P30CA68485).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, CT., Park, KH., Adachi, Y. et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 10, 57–63 (2003). https://doi.org/10.1038/sj.cgt.7700524
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700524
Keywords
This article is cited by
-
The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma
Tumor Biology (2014)
-
Effects of α-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro
Journal of Endocrinological Investigation (2005)
-
Insulin-like growth factors and neoplasia
Nature Reviews Cancer (2004)
-
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity
Oncogene (2004)
-
Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor
Oncogene (2003)